Ipamorelin 10mg Peptide | Third-Party Tested | RemedyX Labs
Order Ipamorelin 10mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.
Ipamorelin is a selective growth-hormone secretagogue peptide that acts on the ghrelin receptor (GHSR-1a) with high selectivity for growth hormone release. It is studied in controlled laboratory models of GH-axis and secretagogue receptor activity. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 49.00 USD
- In stock
- Purity: 99%+
- CAS Number: 170851-70-4
- Molecular Formula: C38H49N9O5
- Molecular Weight: 711.9
- Specification: 10mg/vial
- Contents: Lyophilized Powder
- Appearance: White to Off-White
- Intended Use: Research Only
- SKU: RXL-SKU-0020
Cited Research
Ipamorelin, the First Selective Growth Hormone Secretagogue
This article describes the identification and characterization of ipamorelin as the first selective secretagogue for growth hormone.
PubMed
Ipamorelin, a New Growth-Hormone-Releasing Peptide
This study introduces and investigates the biological activity of the novel growth-hormone-releasing peptide known as ipamorelin.
PubMed
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
This research evaluates the pharmacokinetics of ipamorelin and similar peptidyl growth hormone secretagogues, focusing on nasal absorption pathways.
PubMed, 1998
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
This study establishes pharmacokinetic and pharmacodynamic models for ipamorelin, a growth hormone-releasing peptide, based on data from human volunteers.
PubMed, 1999
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
Researchers investigated whether the growth hormone secretagogue ipamorelin could mitigate the reduction in bone formation caused by glucocorticoids in adult rats.
PubMed, 2001
The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.
This study examined the effects of ipamorelin and GH-releasing peptide-6 on bone mineral content in adult female rats.
PubMed, 2000
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
This study evaluated the ability of the growth-hormone-releasing peptide ipamorelin to stimulate longitudinal bone growth in rats.
PubMed, 1999
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
This proof-of-concept study assessed the use of the ghrelin mimetic ipamorelin for managing postoperative ileus in patients undergoing bowel resection.
PubMed, 2014
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.
Researchers investigated the efficacy of the ghrelin mimetic ipamorelin in treating gastric dysmotility within a rodent model of postoperative ileus.
PubMed, 2012
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
This research involved the development and analysis of a new series of highly potent growth hormone-releasing peptides derived from the ipamorelin scaffold.
PubMed, 1998
Efficacy of ipamorelin on gastric dysmotility in a rodent model of postoperative ileus
Reports accelerated gastric emptying through ghrelin-receptor-mediated mechanisms.
PubMed, 2012
Influence of chronic treatment with ipamorelin on somatotrophs and GH release
Reports changes in somatotroph dynamics and GH release after chronic exposure.
PubMed, 2002